Preliminary Results from a Phase 1-2 Gene Therapy Study of ATA-100, AAV9 Vector Encoding FKRP, in Patients with Limb Girdle Muscular Dystrophy R9
WMS 2024 Oral Presentation Sophie Olivier, MD, Chief Medical Officer, Atamyo Therapeutics
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
